We Need a Global System for Testing and Approving Cancer Treatments
hbr.org
news
2022-10-18 12:05:08

Leer en español Ler em português

By globally harmonizing regulations for the approval of oncology therapies subject to clinical trials, it would be possible to reduce the number of global cancer-related deaths per year by 10% to 20%, or 1 million to 2 million lives. That's because the lack of such an international system is slowing the approval of treatments around the world, according to research that we conducted. The United States has already made significant progress in setting up an international regulatory infrastructure for the simultaneous review and potential approvals of new cancer treatments with Project Orbis, an initiative of the Food and Drug Administration (FDA) Oncology Center of Excellence.
